About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Systemic Diseases group performs translational research based on at least 300 patients with systemic lupus erytomatosus (SLE), antiphospholipid syndrome (APS), systemic sclerosis, vasculitis, dermatomyitis, Sjörgen syndrome or autoinflammatory syndromes in order to better understand their pathogenesis (both at the immunological and genetic regulation level), study their clinical and biological expression (through the detection of new markers that help characterize each of the autoimmune diseases), study morbimortality (through epidemiological studies) and analyse patients' response to medications. With these goals in mind, we seek to improve the diagnosis, clinical monitoring, and prognosis of our patients.
PMID: 33599244 Journal: RHEUMATOLOGY Year: 2021 Reference: Rheumatology (Oxford). 2021 Jun 18;60(6):2615-2628. doi: 10.1093/rheumatology/keab166. Impact factor: 7.58 Publication type: Review in international publication Authors: Tansley, Sarah, Vleugels, Ruth Ann, Werth, Victoria P, Aggarwal, Rohit, Schmidt, Jens, Selva-O'Callaghan, Albert, McHugh, Neil J, Oldroyd, Alexander G S, Allard, Andrew B, Callen, Jeffrey P et al. DOI: 10.1093/rheumatology/keab166
PMID: 32844220 Journal: RHEUMATOLOGY Year: 2021 Reference: Rheumatology (Oxford). 2021 Feb 1;60(2):872-880. doi: 10.1093/rheumatology/keaa401. Impact factor: 7.58 Publication type: Paper in international publication Authors: Pestana-Fernandez, Melani, Rubio-Rivas, Manuel, Tolosa-Vilella, Carles, Guillen-Del-Castillo, Alfredo, Colunga-Arguelles, Dolores, Argibay, Ana, Mari-Alfonso, Begona, Marin-Ballve, Adela, Pla-Salas, Xavier, Chamorro, Antonio-J et al. DOI: 10.1093/rheumatology/keaa401
PMID: 33353469 Journal: ANTIOXIDANTS & REDOX SIGNALING Year: 2021 Reference: Antioxid Redox Signal. 2021 Jun 20;34(18):1420-1427. doi: 10.1089/ars.2020.8230. Epub 2021 Feb 11. Impact factor: 8.401 Publication type: Paper in international publication Authors: Castro-Marrero, Jesus, Domingo, Joan Carles, Cordobilla, Begona, Ferrer, Roser, Giralt, Marina, Alegre-Martin, Jose et al. DOI: 10.1089/ars.2020.8230
PMID: 33493294 Journal: RHEUMATOLOGY Year: 2021 Reference: Rheumatology (Oxford). 2021 Oct 2;60(10):4538-4547. doi: 10.1093/rheumatology/keab027. Impact factor: 7.58 Publication type: Paper in international publication Authors: Garcia-Vives, Eloi, Rodriguez-Palomares, J F, Harty, Len, Solans-Laque, Roser, Jayne, David et al. DOI: 10.1093/rheumatology/keab027
The new technology allows more sensitive detection of scleroderma patients' autoantibodies, which are related to the severity and progression of the disease.
Researchers have used an innovative protocol to identify people with this autoimmune disease who have a higher risk of cancer.
It will allow the promotion of research on systemic autoimmune-based diseases that especially affect women of childbearing age and, therefore, can also appear during pregnancy.
